$0.55
+0.03 (+5.52%)
Open$0.55
Previous Close$0.52
Day High$0.57
Day Low$0.53
52W High$18.25
52W Low—
Volume—
Avg Volume3.77M
Market Cap2.90M
P/E Ratio—
EPS$-25.49
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+4,515.2% upside
Current
$0.55
$0.55
Target
$25.43
$25.43
$14.54
$25.43 avg
$32.33
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.53M | 2.25M | 2.34M |
| Net Income | -604,093 | -536,841 | -566,432 |
| Profit Margin | -23.9% | -23.9% | -24.2% |
| EBITDA | -828,287 | -680,626 | -721,197 |
| Free Cash Flow | -326,986 | -310,260 | -424,378 |
| Rev Growth | -6.1% | -2.1% | -7.6% |
| Debt/Equity | 0.51 | 0.64 | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |